110 related articles for article (PubMed ID: 30530187)
1. Serum Apolipoprotein E and Other Inflammatory Markers Can Identify Non-Responding Patients to a Dendritic Cell Vaccine.
Leeman H; Kaminska E; Green D; Bodman-Smith M; Gravett A; Bodman-Smith K; Copier J; Coulton G; Fusi A; Dalgleish AG
Transl Oncol; 2019 Mar; 12(3):397-403. PubMed ID: 30530187
[TBL] [Abstract][Full Text] [Related]
2. Clinical Benefit of Allogeneic Melanoma Cell Lysate-Pulsed Autologous Dendritic Cell Vaccine in MAGE-Positive Colorectal Cancer Patients.
Toh HC; Wang WW; Chia WK; Kvistborg P; Sun L; Teo K; Phoon YP; Soe Y; Tan SH; Hee SW; Foo KF; Ong S; Koo WH; Zocca MB; Claesson MH
Clin Cancer Res; 2009 Dec; 15(24):7726-7736. PubMed ID: 19996212
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of surgical resection with Gliadel Wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma.
Rudnick JD; Sarmiento JM; Uy B; Nuno M; Wheeler CJ; Mazer MJ; Wang H; Hu JL; Chu RM; Phuphanich S; Black KL; Yu JS
J Clin Neurosci; 2020 Apr; 74():187-193. PubMed ID: 32169363
[TBL] [Abstract][Full Text] [Related]
4. Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial).
Ridolfi L; de Rosa F; Fiammenghi L; Petrini M; Granato AM; Ancarani V; Pancisi E; Soldati V; Cassan S; Bulgarelli J; Riccobon A; Gentili G; Nanni O; Framarini M; Tauceri F; Guidoboni M
BMJ Open; 2018 Aug; 8(8):e021701. PubMed ID: 30082356
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients.
Inogés S; Tejada S; de Cerio AL; Gállego Pérez-Larraya J; Espinós J; Idoate MA; Domínguez PD; de Eulate RG; Aristu J; Bendandi M; Pastor F; Alonso M; Andreu E; Cardoso FP; Valle RD
J Transl Med; 2017 May; 15(1):104. PubMed ID: 28499389
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cell vaccination of patients with metastatic colorectal cancer.
Burgdorf SK
Dan Med Bull; 2010 Sep; 57(9):B4171. PubMed ID: 20816019
[TBL] [Abstract][Full Text] [Related]
7. Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy.
Ribas A; Glaspy JA; Lee Y; Dissette VB; Seja E; Vu HT; Tchekmedyian NS; Oseguera D; Comin-Anduix B; Wargo JA; Amarnani SN; McBride WH; Economou JS; Butterfield LH
J Immunother; 2004; 27(5):354-67. PubMed ID: 15314544
[TBL] [Abstract][Full Text] [Related]
8. Lack of elevation of serum S100B in patients with metastatic melanoma as a predictor of outcome after induction with an autologous vaccine of proliferating tumor cells and dendritic cells.
Schiltz PM; Dillman RO; Korse CM; Cubellis JM; Lee GJ; De Gast GC
Cancer Biother Radiopharm; 2008 Apr; 23(2):214-21. PubMed ID: 18454690
[TBL] [Abstract][Full Text] [Related]
9. Predicted Markers of Overall Survival in Pancreatic Cancer Patients Receiving Dendritic Cell Vaccinations Targeting WT1.
Ito Z; Kan S; Bito T; Horiuchi S; Akasu T; Yoshida S; Kajihara M; Hokari A; Saruta M; Yoshida N; Kobayashi M; Ohkusa T; Shimodaira S; Okamoto M; Sugiyama H; Koido S
Oncology; 2019; 97(3):135-148. PubMed ID: 31216557
[TBL] [Abstract][Full Text] [Related]
10. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.
Gupta S; McCann L; Chan YGY; Lai EW; Wei W; Wong PF; Smithy JW; Weidler J; Rhees B; Bates M; Kluger HM; Rimm DL
J Immunother Cancer; 2019 Sep; 7(1):254. PubMed ID: 31533832
[TBL] [Abstract][Full Text] [Related]
11. Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.
Jan CI; Tsai WC; Harn HJ; Shyu WC; Liu MC; Lu HM; Chiu SC; Cho DY
Front Immunol; 2018; 9():727. PubMed ID: 29910795
[TBL] [Abstract][Full Text] [Related]
12. Blood Eosinophilia is an on-Treatment Biomarker in Patients with Solid Tumors Undergoing Dendritic Cell Vaccination with Autologous Tumor-RNA.
Moreira A; Erdmann M; Uslu U; Vass V; Schuler G; Schuler-Thurner B
Pharmaceutics; 2020 Mar; 12(3):. PubMed ID: 32121531
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cell gene therapy.
Onaitis M; Kalady MF; Pruitt S; Tyler DS
Surg Oncol Clin N Am; 2002 Jul; 11(3):645-60. PubMed ID: 12487060
[TBL] [Abstract][Full Text] [Related]
15. [Allogeneic dendritic cell vaccine pulsed with heat shocked tumor cell lysate can enhance antitumor immunity].
You J; Wang CL; Hao XS
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2785-90. PubMed ID: 18167273
[TBL] [Abstract][Full Text] [Related]
16. In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells.
Stift A; Friedl J; Dubsky P; Bachleitner-Hofmann T; Benkoe T; Brostjan C; Jakesz R; Gnant M
Int J Oncol; 2003 Mar; 22(3):651-6. PubMed ID: 12579320
[TBL] [Abstract][Full Text] [Related]
17. Molecular signatures associated with tumor-specific immune response in melanoma patients treated with dendritic cell-based immunotherapy.
García-Salum T; Villablanca A; Matthäus F; Tittarelli A; Baeza M; Pereda C; Gleisner MA; González FE; López MN; Hoheisel JD; Norgauer J; Gebicke-Haerter PJ; Salazar-Onfray F
Oncotarget; 2018 Mar; 9(24):17014-17027. PubMed ID: 29682201
[TBL] [Abstract][Full Text] [Related]
18. Changes in cytokine and biomarker blood levels in patients with colorectal cancer during dendritic cell-based vaccination.
Burgdorf SK; Claesson MH; Nielsen HJ; Rosenberg J
Acta Oncol; 2009; 48(8):1157-64. PubMed ID: 19863224
[TBL] [Abstract][Full Text] [Related]
19. Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients.
Caballero-Baños M; Benitez-Ribas D; Tabera J; Varea S; Vilana R; Bianchi L; Ayuso JR; Pagés M; Carrera G; Cuatrecasas M; Martin-Richard M; Cid J; Lozano M; Castells A; García-Albéniz X; Maurel J; Vilella R
Eur J Cancer; 2016 Sep; 64():167-74. PubMed ID: 27428073
[TBL] [Abstract][Full Text] [Related]
20. 2003-2013, a valuable study: Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in stage IV breast cancer.
Lin M; Liang S; Jiang F; Xu J; Zhu W; Qian W; Hu Y; Zhou Z; Chen J; Niu L; Xu K; Lv Y
Immunol Lett; 2017 Mar; 183():37-43. PubMed ID: 28143792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
